The following is reprinted from the January 30 issue of the UI Holden Comprehensive Cancer Center’s Holden Highlights newsletter. See other features from this series.

Dr. Michael Wendt, associate professor in Hematology, Oncology and Blood and Marrow Transplantation, has been appointed Co-Leader of the Experimental Therapeutics (ET) Program at the Holden Comprehensive Cancer Center (HCCC), effective January 15, 2024.

Wendt is currently the Director for Translational Breast Cancer Research of the Holden Comprehensive Cancer Center and holds the Arlene Holden Professorship in Breast Cancer Research. He will take on additional key responsibilities for the ET research program, aligning with the strategic plan of the HCCC and in accordance with NCI CCSG aims of the program. His expertise and leadership will be instrumental in guiding the direction of these research efforts.

Wendt’s research interests focuses on understanding the molecular and cellular mechanisms driving cancer progression, immune evasion, and drug resistance in metastatic breast cancer. His work contributes significantly to advancing our knowledge in these critical areas, with the ultimate goal of improving cancer treatments and patient outcomes.

We express gratitude to Drs. Bryan Allen and Aliasger Salem, who previously served as Co-Leaders of the ET program. Their contributions have been invaluable, and we look forward to their continued contributions to the HCCC.

Please join us in extending heartfelt congratulations to Dr. Michael Wendt on his new leadership role in the Experimental Therapeutics Program.